Radiotheranostics in oncology: Making precision medicine possible
Open accessAbstract
A quintessential setting for precision medicine, theranostics refers to a rapidly evolving field of medicine in which disease is diagnosed followed by treatment of disease‐positive patients using tools for the therapy identical or similar to those used for the diagnosis. Against the backdrop of only‐treat‐when‐visualized , the goal is a high therapeutic index with efficacy markedly surpassing toxicity. Oncology leads the way in theranostics innovation, where the approach has become possible with the identification of unique proteins and other factors selectively expressed in cancer versus healthy tissue, advances in imaging technology able to report these tissue factors, and major understanding of targeting chemicals and nanodevices together with methods to attach labels or warheads for imaging and therapy. Radiotheranostics —using radiopharmaceuticals—is becoming routine in patients with prostate cancer and neuroendocrine tumors who express the proteins PSMA (prostate‐specific membrane antigen) and SSTR2 (somatostatin receptor 2), respectively, on their cancer. The palpable excitement in the field stems from the finding that a proportion of patients with large metastatic burden show complete and partial responses, and this outcome is catalyzing the search for more radiotheranostics approaches. Not every patient will benefit from radiotheranostics; but, for those who cross the target‐detected line, the likelihood of response is very high.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Theranostics has the potential to further optimize treatment regimens, potentially reducing the economic burden associated with prolonged or ineffective therapies.
“Additionally, the emergence of theranostics, which combines diagnostics and therapy using radiopharmaceuticals, has the potential to further optimize treatment regimens, potentially reducing the economic burden associated with prolonged or ineffective therapies [128].”
From Radiopharmaceuticals: navigating the frontier of precision medicine and therapeutic innovation (2024) · cites this paper as [128]
The Introduction defines theranostics as integrating targeted diagnostics and treatment, and the Theranostics Audit Trail describes using scans and treatment reviews to guide continuation or restriction of therapy. These passages support the potential to optimize treatment regimens. The paper does not say this would reduce the economic burden of prolonged or ineffective treatment; Optimizing Outcome instead identifies the cost of radiotheranostics as a logistical challenge. No page numbers were available in our copy. (LLM, conf=0.86)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Cancer treatment and survivorship statistics, 2019
Miller, K. D., Nogueira, L., Mariotto, A. B., Rowland, J. H., Yabroff, K. R., Alfano, C. M., Jemal, A., Kramer, J. L., & Siegel, R. L. (2019) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21565 · Cited by 4,253 · see citing works
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
Strosberg, J., El-Haddad, G., Wolin, E., Hendifar, A., Yao, J., Chasen, B., Mittra, E., Kunz, P. L., Kulke, M. H., Jacene, H., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1607427 · Cited by 3,308 · see citing works
Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
Sartor, O., de Bono, J., Chi, K. N., Fizazi, K., Herrmann, K., Rahbar, K., Tagawa, S. T., Nordquist, L. T., Vaishampayan, N., El-Haddad, G., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107322 · Cited by 2,864 · see citing works
Clonal heterogeneity and tumor evolution: past, present, and the future
McGranahan, N., & Swanton, C. (2017) · Cell · doi:10.1016/j.cell.2017.01.018 · Cited by 2,840 · see citing works
Tracking the Evolution of Non–Small-Cell Lung Cancer
Jamal-Hanjani, M., Wilson, G. A., McGranahan, N., Birkbak, N. J., Watkins, T. B. K., Veeriah, S., Shafi, S., Johnson, D. H., Mitter, R., Rosenthal, R., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1616288 · Cited by 2,349 · see citing works
68 Ga-FAPI PET/CT: Tracer Uptake in 28 Different Kinds of Cancer
Kratochwil, C., Flechsig, P., Lindner, T., Abderrahim, L., Altmann, A., Mier, W., Adeberg, S., Rathke, H. G., Röhrich, M., Winter, H., et al. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.119.227967 · Cited by 1,478 · see citing works
Self-citationHofman, M. S., Violet, J. A., Hicks, R. J., Ferdinandus, J., Thang, S. P., Akhurst, T. J., Iravani, A., Kong, G., Kumar, A. S. R., Murphy, D. G., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30198-0 · Cited by 1,184 · see citing works
Hofman, M. S., Emmett, L., Sandhu, S., Iravani, A., Joshua, A. M., Goh, J. C., Pattison, D. A., Tan, T. H., Kirkwood, I. D., Ng, S., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00237-3 · Cited by 1,170 · see citing works
Rebello, R. J., Oing, C., Knudsen, K. E., Loeb, S., Johnson, D. C., Reiter, R. E., Gillessen, S., van der Kwast, T., & Bristow, R. G. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-00243-0 · Cited by 1,159 · see citing works
Radiopharmaceutical therapy in cancer: clinical advances and challenges
Sgouros, G., Bodei, L., McDevitt, M. R., & Nedrow, J. R. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0073-9 · Cited by 980 · see citing works
Lindner, T., Loktev, A., Altmann, A., Giesel, F. L., Kratochwil, C., Debus, J., Jäger, D., Mier, W., & Haberkorn, U. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.210443 · Cited by 947 · see citing works
Self-citationEngineering novel binding proteins from nonimmunoglobulin domains
Binz, H. K., Amstutz, P., & Plückthun, A. (2005) · Nature Biotechnology · doi:10.1038/nbt1127 · Cited by 676 · see citing works
Witzig, T. E., Flinn, I. W., Gordon, L. I., Emmanouilides, C. E., Czuczman, M. S., Saleh, M. N., Cripe, L. D., Wiseman, G. A., Olejnik, T., Multani, P. S., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.11.017 · Cited by 649 · see citing works
Eiber, M., Herrmann, K., Calais, J., Hadaschik, B., Giesel, F. L., Hartenbach, M., Hope, T., Reiter, R., Maurer, T., Weber, W. A., et al. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.198119 · Cited by 626 · see citing works
Development of Fibroblast Activation Protein–Targeted Radiotracers with Improved Tumor Retention
Loktev, A., Lindner, T., Burger, E.-M., Altmann, A., Giesel, F. L., Kratochwil, C., Debus, J., Marmé, F., Jäger, D., Mier, W., et al. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.224469 · Cited by 560 · see citing works
Self-citationRadioimmunotherapy of human tumours
Larson, S. M., Carrasquillo, J. A., Cheung, N. V., & Press, O. W. (2015) · Nature reviews. Cancer · doi:10.1038/nrc3925 · Cited by 540 · see citing works
Xu, X. G., Bednarz, B. P., & Paganetti, H. (2008) · Physics in Medicine and Biology · doi:10.1088/0031-9155/53/13/r01 · Cited by 415 · see citing works
CXC chemokines: the regulatory link between inflammation and angiogenesis
Romagnani, P., Lasagni, L., Annunziato, F., Serio, M., & Romagnani, S. (2004) · Trends in Immunology · doi:10.1016/j.it.2004.02.006 · Cited by 410 · see citing works
Hope, T. A., Eiber, M., Armstrong, W. R., Juarez, R., Murthy, V., Lawhn-Heath, C. A., Behr, S. C., Zhang, L., Barbato, F., Ceci, F., et al. (2021) · JAMA Oncology · doi:10.1001/jamaoncol.2021.3771 · Cited by 365 · see citing works
The Role of the CXCL12/CXCR4/CXCR7 Chemokine Axis in Cancer
Shi, Y. P., Riese, D. J., & Shen, J. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.574667 · Cited by 336 · see citing works
Evans, M. J., Smith-Jones, P. M., Wongvipat, J., Navarro, V., Kim, S., Bander, N. H., Larson, S. M., & Sawyers, C. L. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1106383108 · Cited by 315 · see citing works
Chan, D. L. H., Pavlakis, N., Schembri, G. P., Bernard, E. J., Hsiao, E., Hayes, A. R., Barnes, T. A., Diakos, C. I., Khasraw, M., Samra, J. S., et al. (2017) · Theranostics · doi:10.7150/thno.18068 · Cited by 296 · see citing works
Alberts, I., Hünermund, J., Prenosil, G. A., Mingels, C., Bohn, K. P., Viscione, M., Sari, H., Vollnberg, B., Shi, K., Afshar‐Oromieh, A., et al. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05282-7 · Cited by 286 · see citing works
Herrmann, K., Schottelius, M., Lapa, C., Osl, T., Poschenrieder, A., Hänscheid, H., Lückerath, K., Schreder, M., Bluemel, C., Knott, M., et al. (2015) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.167361 · Cited by 278 · see citing works
Gleisner, K. S., Chouin, N., Gabiña, P. M., Cicone, F., Gnesin, S., Stokke, C., Konijnenberg, M., Cremonesi, M., Verburg, F. A., Bernhardt, P., et al. (2022) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-022-05727-7 · Cited by 272 · see citing works
Gafita, A., Calais, J., Grogan, T. R., Hadaschik, B., Wang, H., Weber, M., Sandhu, S., Kratochwil, C., Esfandiari, R., Tauber, R., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00274-6 · Cited by 271 · see citing works
Self-citationFuture of Theranostics: An Outlook on Precision Oncology in Nuclear Medicine
Langbein, T., Weber, W., & Eiber, M. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.220566 · Cited by 270 · see citing works
Jansen, K., Heirbaut, L., Cheng, J. D., Joossens, J., Ryabtsova, O. V., Cos, P., Maes, L. J. R. M., Lambeir, A., Meester, I. D., Augustyns, K., et al. (2013) · ACS Medicinal Chemistry Letters · doi:10.1021/ml300410d · Cited by 264 · see citing works
Garske-Román, U., Sandström, M., Fröss Baron, K., Lundin, L., Hellman, P., Welin, S., Johansson, S., Khan, T., Lundqvist, H., Eriksson, B., et al. (2018) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-018-3945-z · Cited by 254 · see citing works
Consensus on molecular imaging and theranostics in neuroendocrine neoplasms
Ambrosini, V., Kunikowska, J., Baudin, É., Bodei, L., Bouvier, C., Capdevila, J., Cremonesi, M., de Herder, W. W., Dromain, C., Falconi, M., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.01.008 · Cited by 245 · see citing works
Future cancer research priorities in the USA: a Lancet Oncology Commission
Jaffee, E. M., Dang, C. V., Agus, D. B., Alexander, B. M., Anderson, K. C., Ashworth, A., Barker, A. D., Bastani, R., Bhatia, S. N., Bluestone, J. A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30698-8 · Cited by 211 · see citing works
Lapa, C., Schreder, M., Schirbel, A., Samnick, S., Kortüm, K. M., Herrmann, K., Kropf, S., Einsele, H., Buck, A. K., Wester, H., et al. (2016) · Theranostics · doi:10.7150/thno.16576 · Cited by 203 · see citing works
Delpassand, E. S., Tworowska, I., Esfandiari, R., Torgue, J., Hurt, J., Shafie, A., & Núñez, R. (2022) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.263230 · Cited by 199 · see citing works
Lehrer, E. J., Singh, R. B., Wang, M., Chinchilli, V. M., Trifiletti, D. M., Ost, P., Siva, S., Meng, M.-B., Tchelebi, L. T., & Zaorsky, N. G. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2020.6146 · Cited by 198 · see citing works
Workman, P., Aboagye, E. O., Chung, Y., Griffiths, J. R., Hart, R., Leach, M. O., Maxwell, R. J., McSheehy, P. M. J., Price, P., & Zweit, J. (2006) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djj162 · Cited by 189 · see citing works
Self-citationHope, T. A., Abbott, A., Colucci, K., Bushnell, D. L., Gardner, L., Graham, W. S., Lindsay, S., Metz, D. C., Pryma, D. A., Stabin, M. G., et al. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.230607 · Cited by 183 · see citing works
Werner, R. A., Derlin, T., Lapa, C., Sheikbahaei, S., Higuchi, T., Giesel, F. L., Behr, S. C., Drzezga, A. E., Kimura, H., Buck, A. K., et al. (2019) · Theranostics · doi:10.7150/thno.37894 · Cited by 168 · see citing works
Fendler, W. P., Pabst, K. M., Kessler, L., Costa, P. F., Ferdinandus, J., Weber, M., Lippert, M., Lückerath, K., Umutlu, L., Kostbade, K., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-1432 · Cited by 165 · see citing works
Lapa, C., Herrmann, K., Schirbel, A., Hänscheid, H., Lückerath, K., Schottelius, M., Kircher, M., Werner, R. A., Schreder, M., Samnick, S., et al. (2017) · Theranostics · doi:10.7150/thno.19050 · Cited by 155 · see citing works
First Experience with Chemokine Receptor CXCR4–Targeted PET Imaging of Patients with Solid Cancers
Vág, T., Gerngroß, C., Herhaus, P., Eiber, M. J., Philipp‐Abbrederis, K., Graner, F.-P., Ettl, J., Keller, U. B., Wester, H., & Schwaiger, M. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.161034 · Cited by 147 · see citing works
CXCR4-directed theranostics in oncology and inflammation
Kircher, M., Herhaus, P., Schottelius, M., Buck, A. K., Werner, R. A., Wester, H., Keller, U. B., & Lapa, C. (2018) · Annals of Nuclear Medicine · doi:10.1007/s12149-018-1290-8 · Cited by 144 · see citing works
CXCR4-targeted theranostics in oncology
Buck, A. K., Serfling, S. E., Lindner, T., Hänscheid, H., Schirbel, A., Hahner, S., Faßnacht, M., Einsele, H., & Werner, R. A. (2022) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-022-05849-y · Cited by 133 · see citing works
Blueprint for cancer research: Critical gaps and opportunities
Elmore, L. W., Greer, S. F., Daniels, E. C., Saxe, C. C., Melner, M. H., Krawiec, G. M., Cance, W. G., & Phelps, W. C. (2020) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21652 · Cited by 121 · see citing works
Michalski, K., Ruf, J., Goetz, C., Seitz, A. K., Buck, A. K., Lapa, C., & Hartrampf, P. E. (2020) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-020-05160-8 · Cited by 121 · see citing works
Lapa, C., Lückerath, K., Rudelius, M., Schmid, J.-S., Schoene, A., Schirbel, A., Samnick, S., Pelzer, T., Buck, A. K., Kropf, S., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7063 · Cited by 114 · see citing works
Zevalin: the first radioimmunotherapy approved for the treatment of lymphoma
Grillo-López, A. J. (2002) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2.5.485 · Cited by 108 · see citing works
Sharma, R., Wang, W. M., Yusuf, S., Evans, J. S., Ramaswami, R., Wernig, F., Frilling, A., Mauri, F. A., AL-NAHHAS, A. M., Aboagye, E. O., et al. (2019) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2019.09.003 · Cited by 108 · see citing works
Self-citationAltunay, B., Morgenroth, A., Beheshti, M., Vogg, A. T. J., Wong, N. C. L., Ting, H. H., Biersack, H., Stickeler, E., & Mottaghy, F. M. (2020) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-020-05094-1 · Cited by 107 · see citing works
Jha, A., Taïeb, D., Carrasquillo, J. A., Pryma, D. A., Patel, M. A., Millo, C., de Herder, W. W., Rivero, J. D., Crona, J., Shulkin, B. L., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3703 · Cited by 96 · see citing works
Pretargeting: A Path Forward for Radioimmunotherapy
Cheal, S. M., Chung, S. K., Vaughn, B. A., Cheung, N. V., & Larson, S. M. (2022) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.262186 · Cited by 96 · see citing works
Radioimmunotherapy for B-cell lymphoma: Y90 ibritumomab tiuxetan and I131 tositumomab
Davies, A. J. (2007) · Oncogene · doi:10.1038/sj.onc.1210378 · Cited by 94 · see citing works
Translating insights into tumor evolution to clinical practice: promises and challenges
Fittall, M. W., & Loo, P. V. (2019) · Genome Medicine · doi:10.1186/s13073-019-0632-z · Cited by 88 · see citing works
Buck, A. K., Haug, A. R., Dreher, N., Lambertini, A., Higuchi, T., Lapa, C., Weich, A., Pomper, M. G., Wester, H., Zehnder, A., et al. (2022) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.263693 · Cited by 86 · see citing works
Radiotherapy of oligometastatic prostate cancer: a systematic review
Rogowski, P., Roach, M., Schmidt-Hegemann, N.-S., Trapp, C., von Bestenbostel, R., Shi, R., Büchner, A., Stief, C. G., Belka, C., & Li, M. (2021) · Radiation Oncology · doi:10.1186/s13014-021-01776-8 · Cited by 84 · see citing works
Salaün, P., Campion, L., Bournaud, C., Faivre-Chauvet, A., Vuillez, J.-P., Taïeb, D., Ansquer, C., Rousseau, C., Borson‐Chazot, F., Bardet, S., et al. (2012) · Journal of Nuclear Medicine · doi:10.2967/jnumed.111.101865 · Cited by 82 · see citing works
Bluemel, C., Hahner, S., Heinze, B., Faßnacht, M., Kroiß, M., Bley, T. A., Wester, H., Kropf, S., Lapa, C., Schirbel, A., et al. (2016) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000001435 · Cited by 81 · see citing works
Barbieri, F., Bajetto, A., & Florio, T. (2009) · Journal of Oncology · doi:10.1155/2010/426956 · Cited by 79 · see citing works
CXCR4-Directed Imaging in Solid Tumors
Werner, R. A., Kircher, S., Higuchi, T., Kircher, M., Schirbel, A., Wester, H.-J., Buck, A. K., Pomper, M. G., Rowe, S. P., & Lapa, C. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00770 · Cited by 77 · see citing works
Ma, J., Li, L., Liao, T., Gong, W., & Zhang, C. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.796657 · Cited by 73 · see citing works
Mawad, R., Gooley, T. A., Rajendran, J. G., Fisher, D. R., Gopal, A. K., Shields, A. T., Sandmaier, B. M., Sorror, M. L., Deeg, H. J., Storb, R. F., et al. (2014) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2014.05.014 · Cited by 70 · see citing works
Maurer, S., Herhaus, P., Lippenmeyer, R., Hänscheid, H., Kircher, M., Schirbel, A., Maurer, H. C., Buck, A. K., Wester, H., Einsele, H., et al. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.223420 · Cited by 69 · see citing works
Herhaus, P., Habringer, S., Philipp‐Abbrederis, K., Vág, T., Gerngroß, C., Schottelius, M., Slotta‐Huspenina, J., Steiger, K., Altmann, T., Weißer, T., et al. (2016) · Haematologica · doi:10.3324/haematol.2016.142976 · Cited by 67 · see citing works
Improved Primary Staging of Marginal-Zone Lymphoma by Addition of CXCR4-Directed PET/CT
Duell, J., Krummenast, F., Schirbel, A., Klassen, P., Samnick, S., Rauert‐Wunderlich, H., Rasche, L., Buck, A. K., Wester, H., Rosenwald, A., et al. (2021) · Journal of Nuclear Medicine · doi:10.2967/jnumed.120.257279 · Cited by 67 · see citing works
PSMA Theranostics: Current Landscape and Future Outlook
Zhang, H., Koumna, S., Pouliot, F., Beauregard, J., & Kolinsky, M. P. (2021) · Cancers · doi:10.3390/cancers13164023 · Cited by 64 · see citing works
[68Ga]Ga-Pentixafor PET/MRI for CXCR4 Imaging of Chronic Lymphocytic Leukemia
Mayerhoefer, M. E., Jaeger, U., Staber, P. B., Raderer, M., Wadsak, W., Pfaff, S., Kornauth, C., Senn, D., Weber, M., Wester, H., et al. (2018) · Investigative Radiology · doi:10.1097/rli.0000000000000469 · Cited by 63 · see citing works
Identification of a Novel ITGαvβ6-Binding Peptide Using Protein Separation and Phage Display
Altmann, A., Sauter, M., Roesch, S., Mier, W., Warta, R., Debus, J., Dyckhoff, G., Herold‐Mende, C. C., & Haberkorn, U. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3217 · Cited by 52 · see citing works
Self-citationNanobodies as non-invasive imaging tools
Rashidian, M., & Ploegh, H. L. (2020) · Immuno-Oncology Technology · doi:10.1016/j.iotech.2020.07.001 · Cited by 51 · see citing works
Pandit-Taskar, N. D., Iravani, A., Lee, D., Jacene, H. A., Pryma, D. A., Hope, T. A., Saboury, B., Capala, J., & Wahl, R. L. (2021) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.262977 · Cited by 51 · see citing works
Jacobs, S., Wesseling, P., de Keizer, B., Tolboom, N., Ververs, T. F., Krijger, G. C., Westerman, B. A., Snijders, T. J., Robe, P. A. J. T., & van der Kolk, A. G. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05196-4 · Cited by 50 · see citing works
PET imaging of chemokine receptor CXCR4 in patients with primary and recurrent breast carcinoma
Vág, T., Steiger, K., Rossmann, A., Keller, U. B., Noske, A., Herhaus, P., Ettl, J., Niemeyer, M., Wester, H., & Schwaiger, M. (2018) · EJNMMI Research · doi:10.1186/s13550-018-0442-0 · Cited by 46 · see citing works
In Vivo Targeting of CXCR4—New Horizons
Schottelius, M., Herrmann, K., & Lapa, C. (2021) · Cancers · doi:10.3390/cancers13235920 · Cited by 45 · see citing works
Carlsen, E. A., Johnbeck, C. B., Binderup, T., Loft, M. D., Pfeifer, A., Mortensen, J., Oturai, P., Loft, A., Berthelsen, A. K., Langer, S. W., et al. (2020) · Journal of Nuclear Medicine · doi:10.2967/jnumed.119.240143 · Cited by 44 · see citing works
Zidan, L., Iravani, A., Kong, G., Akhurst, T. J., Michael, M., & Hicks, R. J. (2020) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-020-04915-7 · Cited by 42 · see citing works
Watts, A., Singh, B., Basher, R. K., Singh, H., Bal, A., Kapoor, R. K., Arora, S. K., Wester, H. J., Mittal, B. R., & Behera, D. (2017) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-017-3622-7 · Cited by 35 · see citing works
Vo, P., Gooley, T. A., Rajendran, J. G., Fisher, D. R., Orozco, J. J., Green, D. J., Gopal, A. K., Haaf, R. L., Nartea, M. E., Storb, R. F., et al. (2019) · Haematologica · doi:10.3324/haematol.2019.229492 · Cited by 33 · see citing works
Kraus, S., Dierks, A., Rasche, L., Kertels, O., Kircher, M., Schirbel, A., Zovko, J., Steinbrunn, T., Tibes, R., Wester, H., et al. (2021) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.262206 · Cited by 33 · see citing works
Targeting dormant micrometastases: rationale, evidence to date and clinical implications
Hurst, R. E., Bastian, A., Bailey‐Downs, L. C., & Ihnat, M. A. (2016) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834015624277 · Cited by 29 · see citing works
Outcomes of metastasis-directed therapy of bone oligometastatic prostate cancer
Rogowski, P., Trapp, C., von Bestenbostel, R., Schmidt-Hegemann, N.-S., Shi, R., Ilhan, H., Kretschmer, A., Stief, C. G., Ganswindt, U., Belka, C., et al. (2021) · Radiation Oncology · doi:10.1186/s13014-021-01849-8 · Cited by 27 · see citing works
Stumpf, C., Kaemmerer, D., Neubauer, E., Sänger, J., Schulz, S., & Lupp, A. (2018) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-018-2722-5 · Cited by 26 · see citing works
Phase I Study of a CD45-Targeted Antibody–Radionuclide Conjugate for High-Risk Lymphoma
Cassaday, R. D., Press, O. W., Pagel, J. M., Rajendran, J. G., Gooley, T. A., Fisher, D. R., Holmberg, L., Miyaoka, R. S., Sandmaier, B. M., Green, D. J., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1567 · Cited by 26 · see citing works
Identification of Ligands and Translation to Clinical Applications
Haberkorn, U., Mier, W., Kopka, K., Herold‐Mende, C. C., Altmann, A., & Babich, J. W. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.186791 · Cited by 19 · see citing works
Self-citationTuazon, S. A., Sandmaier, B. M., Gooley, T. A., Fisher, D. R., Holmberg, L., Becker, P. S., Lundberg, S. J., Orozco, J. J., Gopal, A. K., Till, B. G., et al. (2020) · Bone Marrow Transplantation · doi:10.1038/s41409-020-01000-3 · Cited by 19 · see citing works
Total-body dynamic PET/CT of micro-metastatic lymph node in a patient with lung cancer
Fu, F., Li, X., Wu, Y., Xu, J., Bai, Y., Gao, Y., Wang, Z., Zhang, W., Wei, W., Fakhri, G. E., et al. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-020-05121-1 · Cited by 19 · see citing works
[18F]FET-βAG-TOCA: The Design, Evaluation and Clinical Translation of a Fluorinated Octreotide
Allott, L., Dubash, S., & Aboagye, E. O. (2020) · Cancers · doi:10.3390/cancers12040865 · Cited by 15 · see citing works
Self-citationMaluf, F. C., Pereira, F. M. T., Usón, P. L. S., Bastos, D. A., da Rosa, D. A. R., Wiermann, E. G., Schutz, F. A. B., Kater, F., de Oliveira, F. N. G., Monteiro, F. S. M., et al. (2021) · JCO Global Oncology · doi:10.1200/go.20.00505 · Cited by 15 · see citing works
Epigenetic changes in gastroenteropancreatic neuroendocrine tumours
Mapelli, P., Aboagye, E. O., Stebbing, J., & Sharma, R. (2014) · Oncogene · doi:10.1038/onc.2014.379 · Cited by 14 · see citing works
Self-citationTuazon, S. A., Cassaday, R. D., Gooley, T. A., Sandmaier, B. M., Holmberg, L., Smith, S. D., Maloney, D. G., Till, B. G., Martin, D. B., Chow, V. A., et al. (2020) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2020.09.021 · Cited by 12 · see citing works
Zoller, F., Markert, A., Barthe, P., Zhao, W., Weichert, W., Askoxylakis, V., Altmann, A., Mier, W., & Haberkorn, U. (2012) · Angewandte Chemie · doi:10.1002/ange.201203857 · Cited by 10 · see citing works
Self-citationLigand engineering for theranostic applications
Altmann, A., Kratochwil, C., Giesel, F. L., & Haberkorn, U. (2021) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2021.04.006 · Cited by 9 · see citing works
Self-citation
Flagged first, then by citations
1 of the 90 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Radiopharmaceuticals and their applications in medicine
Zhang, S., Wang, X., Gao, X., Chen, X., Li, L., Li, G., Liu, C., Miao, Y., Wang, R., & Hu, K. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02041-6 · Cited by 317 · see citing works
Lammers, T. (2024) · Advanced Materials · doi:10.1002/adma.202312169 · Cited by 295 · see citing works
Ahmed, A., Xi, R., Hou, M., Shah, S. A., & Hameed, S. (2023) · IEEE Access · doi:10.1109/access.2023.3323574 · Cited by 154 · see citing works
Radiopharmaceuticals: navigating the frontier of precision medicine and therapeutic innovation
Dhoundiyal, S., Srivastava, S., Kumar, S., Singh, G., Ashique, S., Pal, R., Mishra, N., & Taghizadeh-Hesary, F. (2024) · European Journal of Medical Research · doi:10.1186/s40001-023-01627-0 · Cited by 144 · see citing works
“Additionally, the emergence of theranostics, which combines diagnostics and therapy using radiopharma-ceuticals, has the potential to further optimize treatment regimens, potentially reducing the economic burden associated with prolonged or ineffective therapies [128].”
BackgroundNew strategies for lung cancer diagnosis and treatment: applications and advances in nanotechnology
Feng, J., Zhang, P., Wang, D., Li, Y., & Tan, J. (2024) · Biomarker Research · doi:10.1186/s40364-024-00686-7 · Cited by 53 · see citing works
161Tb-PSMA Unleashed: a Promising New Player in the Theranostics of Prostate Cancer
Al‐Ibraheem, A., & Scott, A. M. (2023) · Nuclear Medicine and Molecular Imaging · doi:10.1007/s13139-023-00804-7 · Cited by 47 · see citing works
Biomaterials with cancer cell-specific cytotoxicity: challenges and perspectives
Chu, Z., Wang, W., Zheng, W., Fu, W., Wang, Y., Wang, H., & Qian, H. (2024) · Chemical Society Reviews · doi:10.1039/d4cs00636d · Cited by 45 · see citing works
Advances in Radioligand Theranostics in Oncology
Lawal, I. O., Abubakar, S., Ndlovu, H., Mokoala, K. M. G., More, S. S., & Sathekge, M. M. (2024) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-024-00702-4 · Cited by 43 · see citing works
Bragina, O., Чернов, В. И., Ларькина, М. С., Rybina, A., Zelchan, R., Garbukov, Е. Y., Oroujeni, M., Loftenius, A., Orlova, A., Sörensen, J., et al. (2023) · Theranostics · doi:10.7150/thno.86770 · Cited by 42 · see citing works
Filippi, L., Urso, L., Bianconi, F., Palumbo, B., Marzola, M. C., Evangelista, L., & Schillaci, O. (2023) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2023.2192351 · Cited by 37 · see citing works
Zhang, S., Ma, X., Jiang, W., Shen, J., Shi, Y., Wang, X., Xie, L., Sun, X., Wu, Y., Tian, H., et al. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.07.006 · Cited by 32 · see citing works
Larouze, A., Alcocer‐Ávila, M., Morgat, C., Champion, C., & Hindié, E. (2023) · Journal of Nuclear Medicine · doi:10.2967/jnumed.123.265509 · Cited by 30 · see citing works
Huang, J., Zhang, X., Liu, Q., Gong, F., Huang, Y., Huang, S., Fu, L., & Tang, G. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01812 · Cited by 26 · see citing works
Molecular imaging of renal cell carcinomas: ready for prime time
Wu, Q., Shao, H., Zhai, W., Huang, G., Liu, J., Calais, J., & Wei, W. (2024) · Nature Reviews Urology · doi:10.1038/s41585-024-00962-z · Cited by 22 · see citing works
Meng, L., Fang, J., Lin, X., Zhuang, R., Huang, L., Li, Y., Zhang, X., & Guo, Z. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.113757 · Cited by 20 · see citing works
Yang, Y., Liu, X., Zhang, R., Liu, Y., Zhou, N., & Jiang, Y. (2025) · Small · doi:10.1002/smll.202409593 · Cited by 19 · see citing works
Kazuta, N., Nakashima, K., Watanabe, H., & Ono, M. (2024) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.4c00257 · Cited by 19 · see citing works
Li, Z., Ruan, Q. Z., Jiang, Y., Wang, Q., Yin, G., Feng, J., & Zhang, J. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01608 · Cited by 19 · see citing works
Zhou, X., Shi, B., Huang, G., Liu, J., & Wei, W. (2024) · Trends in cancer · doi:10.1016/j.trecan.2024.08.006 · Cited by 18 · see citing works
Enhanced chemotherapy and anti-metastasis with in situ nanosphere-to-nanofiber transition
Zhang, H., Peng, L., Qin, W., Jia, D., Zhao, R., Jiang, M., Ji, M. H., Wang, L., Li, G., & Zheng, Z. (2023) · Nano Today · doi:10.1016/j.nantod.2023.102122 · Cited by 18 · see citing works
Biomarker-Driven Approaches to Bone Metastases: From Molecular Mechanisms to Clinical Applications
Elshimy, Y., Alkhatib, A. R., Atassi, B., & Mohammad, K. S. (2025) · Biomedicines · doi:10.3390/biomedicines13051160 · Cited by 19 · see citing works
Hou, H., Pan, Y., Wang, Y., Ma, Y., Niu, X., Sun, S., Hou, G., Tao, W., & Gao, F. (2024) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-024-06726-6 · Cited by 16 · see citing works
Hindié, E., Larouze, A., Alcocer‐Ávila, M., Morgat, C., & Champion, C. (2024) · Theranostics · doi:10.7150/thno.95436 · Cited by 16 · see citing works
The tumor microenvironment across four dimensions: assessing space and time in cancer biology
Larson, C. R., Mandloi, A., Acharyya, S., & Carstens, J. L. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1554114 · Cited by 14 · see citing works
Liu, Y., Oroujeni, M., Liao, Y., Vorobyeva, A., Васильевна, Б. В., Orlova, A., Konijnenberg, M., Carlqvist, M., Wahlberg, E., Loftenius, A., et al. (2024) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-024-06840-5 · Cited by 14 · see citing works
Kauffman, N., Morrison, J., O’Brien, K., Fan, J., & Zinn, K. R. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15041138 · Cited by 13 · see citing works
Nuclear Medicine and Molecular Imaging in Urothelial Cancer: Current Status and Future Directions
McDonald, S., Keane, K. G., Gauci, R., & Hayne, D. (2025) · Cancers · doi:10.3390/cancers17020232 · Cited by 13 · see citing works
An, Y., Gu, W., Miao, M., Miao, J., Zhou, H., Zhao, M., Jiang, Y., Li, Q., & Miao, Q. (2023) · Analytical Chemistry · doi:10.1021/acs.analchem.3c02578 · Cited by 13 · see citing works
Approaching Gallium-68 radiopharmaceuticals for tumor diagnosis: a Medicinal Chemist's perspective
Musumeci, F., Fasce, A., Falesiedi, M., Oleari, F., Grossi, G., Carbone, A., & Schenone, S. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117760 · Cited by 12 · see citing works
Ayalew, B. D., Abdullah, A., Khan, S. M., Alemayehu, Z. G., Teferi, M. G., Aboye, B. T., Woldeyohannes, E. M., Sime, B. L., Tewodros, Y. T., & Hundisa, M. I. (2025) · ONCOLOGIE · doi:10.1515/oncologie-2024-0543 · Cited by 12 · see citing works
Lu, Z., Shi, M., Zheng, X., Liang, Y., Wang, J., Zou, Z., Luo, R., Feng, M., Yang, X., Zhou, Y., et al. (2024) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2024.124946 · Cited by 11 · see citing works
Deep learning in nuclear medicine: from imaging to therapy
Zhang, M.-X., Liu, P., Zhang, M.-D., Su, P., Shang, H.-S., Zhu, J., Wang, D., Ji, X., & Liao, Q.-M. (2025) · Annals of Nuclear Medicine · doi:10.1007/s12149-025-02031-w · Cited by 11 · see citing works
Obeid, K., Kanellopoulos, P., Abouzayed, A., Mattsson, A., Максимилианович, Т. В., Nock, B. A., Μάινα, Θ., & Orlova, A. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16040513 · Cited by 10 · see citing works
Lymphoma-Sink Effect in Marginal Zone Lymphoma Based on CXCR4-Targeted Molecular Imaging
Kosmala, A., Seifert, S., Schneid, S., Dreher, N., Higuchi, T., Weich, A., Serfling, S. E., Hartrampf, P. E., Einsele, H., Buck, A. K., et al. (2023) · Molecular Imaging and Biology · doi:10.1007/s11307-023-01830-9 · Cited by 9 · see citing works
Shi, J., & Liu, S. (2024) · iRadiology · doi:10.1002/ird3.55 · Cited by 9 · see citing works
Nrf2 in human cancers: biological significance and therapeutic potential
Tian, Y. (2024) · American Journal of Cancer Research · doi:10.62347/lzvo6743 · Cited by 9 · see citing works
Søndergaard, U., Thomas, K. E., Pedersen, K. S., Kranz, M., Sundset, R., Moldes‐Anaya, A., & Jensen, M. (2024) · Applied Radiation and Isotopes · doi:10.1016/j.apradiso.2024.111551 · Cited by 8 · see citing works
Winuprasith, T., Koirala, P., McClements, D. J., & Khomein, P. (2023) · International Journal of Nanomedicine · doi:10.2147/ijn.s416737 · Cited by 8 · see citing works
New spectroscopic data on odd-parity autoionization states of atomic lutetium
Jun-Yao, Z., Lu, X., Yunfei, L., & Jun-Jie, C. (2024) · The European Physical Journal D · doi:10.1140/epjd/s10053-024-00892-w · Cited by 8 · see citing works
Gan, R.-H., Lan, L.-Q., Sun, D.-N., Tang, F., Niu, G., Zheng, D., Wang, B., & Lu, Y. (2024) · Scientific Reports · doi:10.1038/s41598-024-71277-7 · Cited by 7 · see citing works
Salgueiro, M. J., & Zubillaga, M. B. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17091159 · Cited by 7 · see citing works
Dual-targeted alpha therapy mitigates prostate cancer and boosts immune checkpoint blockade therapy
Sun, J., Yang, J., Guo, J., Tao, L., Xu, B., Wang, G., Meng, F., & Zhong, Z. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.113686 · Cited by 7 · see citing works
Li, Y., Zhang, X., Ren, R., Tang, H., Zhu, A., Zhu, S., Zhang, Y., Feng, N., Shao, A., & Ni, J. (2025) · Chinese Chemical Letters · doi:10.1016/j.cclet.2025.111145 · Cited by 6 · see citing works
Luo, Y., Xu, Y., Li, W., Hua, Y., Shen, Q., Wang, J., Chen, L., Fu, H., Lin, J., & Yu, C. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c00637 · Cited by 6 · see citing works
Xu, B., Tao, L., Sun, J., Yang, J., Meng, F., & Zhong, Z. (2025) · APOPTOSIS · doi:10.1007/s10495-025-02136-7 · Cited by 6 · see citing works
18F-/68Ga-Labeled Peptide-Based Probes for PET Imaging of ROR1 Expression
Yang, T., Sun, J., Huang, G., Wang, H., He, Z., Lin, S., Wang, Y., Zhuang, R., Zhang, X., Liu, H., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c02016 · Cited by 6 · see citing works
Yamaguchi, K., Kazuta, N., Tsuchihashi, S., Watanabe, H., & Ono, M. (2024) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2024.108945 · Cited by 6 · see citing works
Tumor microenvironment‐responsive drug self‐delivery systems to treat cancer and overcome MDR
Li, L., Xie, Y.-P., Qin, Y., Chu, H.-P., Xie, H., Zang, D., & Liu, T. (2024) · Rare Metals · doi:10.1007/s12598-024-02892-6 · Cited by 6 · see citing works
Njotu, F. N., Ketchemen, J. P., Babeker, H., Henning, N. W., Tikum, A. F., Nwangele, E., Monzer, A., Hassani, N., Gray, B. D., Pak, K. Y., et al. (2024) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-024-07011-2 · Cited by 7 · see citing works
Precision Medicine: Personalizing The Fight Against Cancer
Mahmood, A. A. R., Jha, A. M., & Manivannan, K. (2024) · International Journal of Trends in OncoScience · doi:10.22376/ijtos.2023.2.1.10-18 · Cited by 6 · see citing works
Maskur, Wongso, H., Humani, T. S., Effendi, N., Palangka, C. R. A. P., Pujiyanto, A., Setiawan, H., Juliyanto, S., Ridwan, M., & Ritawidya, R. (2024) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2024.106104 · Cited by 6 · see citing works
Diatom Biosilica: A Useful Natural Material for Biomedical Engineering
Yoo, D., Lee, M., Seo, Y., Yoon, J., Jang, E., Lee, G., Kwon, D., Lee, S. D., Min, J., & Lee, T. (2025) · Water · doi:10.3390/w17162373 · Cited by 5 · see citing works
Rahimian, S., Najafi, H., & Doroudian, M. (2025) · Medical Oncology · doi:10.1007/s12032-025-02924-w · Cited by 5 · see citing works
Munekane, M., Ozaki, M., Mitani, Y., Sakaida, N., Sano, K., Yamasaki, T., Mukai, T., Mishiro, K., Fuchigami, T., & Ogawa, K. (2024) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.4c00732 · Cited by 5 · see citing works
Kazuta, N., Tsuchihashi, S., Watanabe, H., & Ono, M. (2024) · Annals of Nuclear Medicine · doi:10.1007/s12149-024-01930-8 · Cited by 5 · see citing works
Biochemical Precision: Enzyme-Responsive Drug Delivery Systems in Cancer Therapy
Narkhede, M., Akanksha, K., & Nilesh, W. (2025) · Current Enzyme Inhibition · doi:10.2174/0115734080363073250723061416 · Cited by 4 · see citing works
Navigating the safety profile of Actinium-225 targeted alpha therapy: a comprehensive review
Roustaei, H., D’Alessandria, C., & Decristoforo, C. (2025) · Clinical and Translational Imaging · doi:10.1007/s40336-025-00733-9 · Cited by 4 · see citing works
Radiopharmaceuticals: Status, Regulatory Landscape and Future Perspective
Maithania, H. V., John, R., Painoori, R., monpara, J., Swaminathan, S., & Kalhapure, R. S. (2026) · AAPS PharmSciTech · doi:10.1208/s12249-026-03346-1 · Cited by 4 · see citing works
Gu, W., Zhang, Y., Chen, W., Zhu, J., Zhang, Y., Cheng, B., Li, Q., & Miao, Q. (2024) · ACS Materials Letters · doi:10.1021/acsmaterialslett.4c01564 · Cited by 4 · see citing works
Revitalizing PI3K Inhibitors for PET/CT Imaging and Radionuclide Therapy of Multiple Cancers
Huang, H., Peng, S., Zuo, Q., Zhang, S., Wu, J., Zhang, Y., Chen, X., Lu, Q., Hu, Q., Jiang, S., et al. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c03583 · Cited by 4 · see citing works
Hindié, E., Köster, U., Champion, C., Zanotti‐Fregonara, P., & Morgat, C. (2024) · EJNMMI Physics · doi:10.1186/s40658-024-00699-z · Cited by 4 · see citing works
Li, Z., Duan, X., Han, P., Yin, G., Jiang, Y., Ruan, Q. Z., & Zhang, J. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c02656 · Cited by 4 · see citing works
A Cyclic Peptide‐Based Radiotheranostic Agent for Urokinase‐Type Plasminogen Activator in Tumors
Wang, X., Dai, D., Shen, J., Zhang, S., Ohkubo, T., Xie, L., Zhang, Y., Li, G., Liu, C., Tian, H., et al. (2025) · Chemistry - A European Journal · doi:10.1002/chem.202500479 · Cited by 4 · see citing works
Sharma, D., Carter, H., Sannachi, L., Cui, W., Giles, A., Saifuddin, M., & Czarnota, G. J. (2023) · Technology in Cancer Research & Treatment · doi:10.1177/15330338231200993 · Cited by 4 · see citing works
CXCR4-targeted Theranostics in Hematooncology: Opportunities and Challenges
Werner, R. A., Haug, A. R., Buske, C., Heidegger, S. M., Illert, A. L., Bassermann, F. C., Herhaus, P., Buck, A. K., Duell, J., Topp, M. S., et al. (2024) · Nuklearmedizin - NuclearMedicine · doi:10.1055/a-2194-9965 · Cited by 4 · see citing works
The role of radiotheranostics in personalized treatment for breast cancer
Sharma, D., Srivastava, S., Kagithala, N. R., Rahate, K., & Sridhar, S. B. (2025) · Medical Oncology · doi:10.1007/s12032-025-02825-y · Cited by 3 · see citing works
Ding, D., Feng, J., Yin, G., Jiang, Y., Li, Z., Han, P., & Zhang, J. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c03078 · Cited by 3 · see citing works
Chen, G., Qin, Y., & Sheng, R. (2024) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.4c00614 · Cited by 3 · see citing works
Yu, X., Yang, X., Nie, H., Jiang, W., He, X., & Ou, C. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1255809 · Cited by 3 · see citing works
Sreedevi, B., Kishore, D. N., Ghosh, S., & Kaur, G. (2024) · International Journal of Trends in OncoScience · doi:10.22376/ijtos.2024.2.1.19-26 · Cited by 3 · see citing works
Palma, M. D., Salvarese, N., Gobbi, C., Dolmella, A., & Bolzati, C. (2023) · ChemRxiv · doi:10.26434/chemrxiv-2023-gxkj5 · Cited by 3 · see citing works
Theranostics, Advanced Cancer, and The Meaning of Life
Turner, J. H. (2024) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2024.0176 · Cited by 2 · see citing works
Chelating positron-emitting radiometals for molecular imaging
Hong, Z. (2024) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2024.216420 · Cited by 2 · see citing works
Wang, W., Yan, Y., & Huang, J. (2025) · Tetrahedron · doi:10.1016/j.tet.2025.134727 · Cited by 2 · see citing works
Organosilicon precursors for efficient aromatic copper-mediated radiocyanation
Wright, J. S., Ma, R., McCarthy, C. J., Kaup, G., George, E. N., Priest, J. D., Webb, E., Cheng, K., Bowden, G. D., Brooks, A. F., et al. (2025) · Chem · doi:10.1016/j.chempr.2025.102707 · Cited by 2 · see citing works
Gong, J., Wang, Q., Wang, R., Chen, J., Gao, J., Du, J., & Li, J. (2025) · Nanoscale Advances · doi:10.1039/d5na00270b · Cited by 2 · see citing works
Radiotheranostics in Low- and Middle-Income Countries: Challenges, Practice, and Prospects
Lawal, I. O., Ndlovu, H., Kabunda, J., Mokoala, K. M. G., & Sathekge, M. M. (2025) · World Journal of Nuclear Medicine · doi:10.1055/s-0045-1812307 · Cited by 2 · see citing works
Fourie, H., Bolcaen, J., Peterson, S., & Zeevaart, J. R. (2025) · Physics in Medicine and Biology · doi:10.1088/1361-6560/ae2b48 · Cited by 2 · see citing works
Development of galectin-3 targeted radioimmunoligands for cancer theranostics
Zhang, S., Hu, Q., Lu, Q., Wu, J., Li, Z., Wan, Y., Huang, H., Chen, X., Liu, C., Tian, H., et al. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.12.028 · Cited by 2 · see citing works
Covalent Radiopharmaceuticals: Precision Imaging and Therapy for Cancer
Klauser, P. C., & Wang, L. (2026) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5c01912 · Cited by 2 · see citing works
Zhao, L., Bai, L., Sun, L., Liu, X., Lu, X., Zhang, J., Xu, X., & Song, S. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6c00837 · Cited by 2 · see citing works
The Future of Radioactive Medicine
Sproull, M. T., Wilson, E., Miller, R., & Camphausen, K. A. (2023) · Radiation Research · doi:10.1667/rade-23-00031.1 · Cited by 2 · see citing works
Theranostics as an Emerging Integrated Imaging and Therapies in Precision Oncology
Taleuzzaman, M., Chauhan, S., Singh, H. K., & Khan, S. (2024) · Springer eBooks · doi:10.1007/978-981-97-3115-2_12 · Cited by 2 · see citing works
Kaushal, A. (2023) · Qeios · doi:10.32388/dy0rcf · Cited by 2 · see citing works
Kaushal, A. (2023) · Qeios · doi:10.32388/dy0rcf.2 · Cited by 2 · see citing works
Yang, Z., Barnes, C., Domarkas, J., Koch‐Paszkowski, J., Wright, J., Amgheib, A., Renard, I., Fu, R., Archibald, S. J., Aboagye, E. O., et al. (2023) · Reaction Chemistry & Engineering · doi:10.1039/d3re00307h · Cited by 1 · see citing works
Self-citationSun, J., Yang, J., Guo, J., Xu, B., Tao, L., Zhao, X., Wang, G., Meng, F., & Zhong, Z. (2025) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2025.114945 · Cited by 1 · see citing works
Soni, U., Thorat, V. G., & Pujari, R. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-34199-1.00013-2 · Cited by 1 · see citing works
Theranostics in Sarcoma: A Critical Review of Current Evidence and Future Potential
Appana, O., Konieczkowski, D., & Tinoco, G. (2026) · Current Treatment Options in Oncology · doi:10.1007/s11864-026-01386-0 · Cited by 1 · see citing works
Radiotheranostics With Nanoparticles: Precision Targeting in Receptor‐Overexpressing Tumors
Cheruiyot, E. J., Wanjeh, D. M., Birir, J. K., Karuga, S., Amugune, B. K., Chambers, C., Lewis, M. R., Smith, C. J., & Sakr, T. M. (2026) · Journal of Labelled Compounds and Radiopharmaceuticals · doi:10.1002/jlcr.70028 · Cited by 1 · see citing works
Li, R., Cao, R., Zhang, G., Ding, L., Lai, C., Liu, E., Qian, K., Tan, B., Zhu, J., Song, M., et al. (2026) · Journal of Nuclear Medicine · doi:10.2967/jnumed.125.271421 · Cited by 1 · see citing works
The Present and Future of THERANOSTICS
Lam, W. W.-C., Thang, S. P., Loke, K. S. H., Ngam, P. I., Tan, A. E., Cheng, L. T., Yu, S., Ler, A. S. L., Khor, D. L., Somanesan, S., et al. (2026) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.70126 · Cited by 1 · see citing works
Imaging of ROR1 expression in tumors using radiolabeled affibody molecules
Westerberg, C., Xu, T., Marth, M., Ud‐din, M., Abushaia, R., Hagelin, T., Ståhl, S., Orlova, A., Максимилианович, Т. В., Löfblom, J., et al. (2026) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-026-08106-8 · Cited by 1 · see citing works
Editorial: The development of lethal prostate cancer
Zhang, B., Qu, S., Li, X., Ci, X., & Jiang, C. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1156392 · Cited by 1 · see citing works
Zhang, R. (2023) · Oncology Advances · doi:10.14218/ona.2023.00024
Improving Prostate Cancer Patient Care in the Clinical Setting
Deinert, J., & Leah K. Shaw, M. (2024) · Journal of the Advanced Practitioner in Oncology · doi:10.6004/jadpro.2024.15.3.9
2022–2023 Drug Updates in Solid Tumors
Holle, L. M. (2024) · Journal of the Advanced Practitioner in Oncology · doi:10.6004/jadpro.2024.15.3.3
Ibrahim, A. A. (2024) · Bangladesh Journal of Nuclear Medicine · doi:10.3329/bjnm.v27i1.71505
Historique de la radiothérapie interne vectorisée (RIV)
Barbet, J. (2024) · Médecine Nucléaire · doi:10.1016/j.mednuc.2024.11.006
Advances with radiopharmaceutical therapy in cancer
Lepareur, N. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-29808-0.00002-9
- Authors
- Aboagye, E. O., Barwick, T. D., & Haberkorn, U.
- Affiliations
- Hammersmith Hospital (GB)
- National Health Service (GB)
- German Cancer Research Center (DE)
- Corresponding author
- Aboagye, Eric O.
- Venue
- CA: A Cancer Journal for Clinicians
- Publisher
- Wiley
- Published
- 2023-01-09
- Volume
- 73
- Issue
- 3
- Pages
- 255-274
- ISSN
- 0007-9235 (ISSN-L)
- 1542-4863
- OpenAlex
- W4313837147
- Cited by
- 131
- References
- 90
- Citations by year
- 2026: 30 · 2025: 41 · 2024: 41 · 2023: 19
- FWCI
- 5.52
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- CA A Cancer Journal for Clinicians (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Cancer Research UK (A25149, C2536/A28680)
- National Institute for Health and Care Research (WSCC_P62585)
- Imperial College London
- Deutsche Forschungsgemeinschaft (HA 2901/12-1)
- Bundesministerium für Bildung und Forschung
- Medical Research Council (MR/N020782/1)
- Topics
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiopharmaceutical Chemistry and Applications
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
- Health Sciences › Medicine › Epidemiology › Neuroendocrine Tumor Research Advances
- Keywords
- radiotheranostics, theranostics, precision medicine, radiopharmaceuticals, prostate-specific membrane antigen, somatostatin receptor 2, prostate cancer, neuroendocrine tumors, targeted radionuclide therapy, tumor imaging, metastatic cancer, therapeutic index
- MeSH terms
- Humans, Male, Medical Oncology, Prostatic Neoplasms, Neuroendocrine Tumors, Radiopharmaceuticals, Precision Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
